Viatris

VTRSHealth carePharmaceuticals

Compare

$19.22

Close on Nov 4, 2026

$22.1B

What does Viatris do?

Viatris makes generic and off-patent medicines sold around the world.

Revenue by segment

Fiscal year 2025

Developed Markets59.7%
Greater China16.4%
Emerging Markets15.5%
Japan, Australia and New Zealand8.4%

As reported in the company's annual report (10-K).

Stock price

Useful context, but not the main focus.

+83.2% over the past year

Drag across the chart to compare two days.Touch the chart with two fingers to compare two days.

Key financial information

What it is · Why it matters · How to read it in context.

Fiscal year 2025, ended December 2025 · U.S. dollarsClick any metric to see what it means.

$14.3B
Previous year:
$14.7B
−3.0%
Previous year:
−4.5%
+7.1%
−$3.51B
Previous year:
−$634.2M
−24.6%
Previous year:
−4.3%
13.0%
$1.94B
Positive in each of the last 5 years
$886.5M/$13.4B
Cash6%
$886.5M
Debt94%
$13.4B
As of Jun 30, 2026
N/A
Last 12 months
Not meaningful: earnings over the last 12 months were negative.
32.1
2.5%
Paid over the last 12 months: $0.48 per share

5-year trends

Annual figures, fiscal years 2021-2025.

Financial figures come from company filings with the U.S. Securities and Exchange Commission (SEC). Latest filing used: August 6, 2026. Stock prices are end-of-day closing prices.